Biochip for K-ras Mutation Screening in Ovarian Cancer-Reference-Cited by-同舟云学术

Biochip for K-ras Mutation Screening in Ovarian Cancer

Published:2005-04-01 Issue:4 Volume:51 Page:784-787
ISSN:0009-9147
Container-title:Clinical Chemistry
language:en
Short-container-title:

Author:

Fabjani Gerhild¹²,Kriegshaeuser Gernot³,Schuetz Andreas⁴,Prix Lothar⁴,Zeillinger Robert¹³

Affiliation:

1. Department of Obstetrics and Gynecology, Division of Gynecology, Medical University of Vienna, Vienna, Austria

2. Ludwig Boltzmann Institute for Gynecology and Gynecologic Oncology, Vienna, Austria

3. ViennaLab Labordiagnostika GmbH, Vienna, Austria

4. Biofocus GmbH, Recklinghausen, Germany

Publisher

Oxford University Press (OUP)

Subject

Biochemistry (medical),Clinical Biochemistry

Link

http://academic.oup.com/clinchem/article-pdf/51/4/784/32683547/clinchem0784.pdf

Reference20 articles.

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin1999;49:8-31.

2. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer [Review]. Int J Oncol2000;16:567-576.

3. Bos JL. ras oncogenes in human cancer: a review. Cancer Res1989;49:4682-4689.

4. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol1991;139:777-785.

5. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res1993;53:3103-3108.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas;Archives of Gynecology and Obstetrics;2020-06-16

2. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms;Oncotarget;2016-11-18

3. Low-grade serous carcinoma: New concepts and emerging therapies;Gynecologic Oncology;2013-09

4. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer;Diagnostic Pathology;2013-06-25

5. Ovarian cancer as a genetic disease;Frontiers in Bioscience;2013